Recently Visited
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
Most Searched
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
Search results for {{searchTermHome}}
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} | Score
{{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
No Matches Found
Alimera Sciences, Inc.
Who are in the management team of Alimera Sciences, Inc.?
Loading...
What does Alimera Sciences, Inc. do?
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing prescription ophthalmic drugs for retinal diseases. As of June 2024, it reported net sales of $27 million and a market cap of $301.29 million, with a net profit of -$3 million.
How big is Alimera Sciences, Inc.?
As of Sep 17, Alimera Sciences, Inc. has a market capitalization of 301.29 million, with net sales of 99.68 million and a net profit of -14.69 million over the last four quarters. The company's shareholder's funds are 46.17 million, and total assets are 153.52 million as of Dec 23.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read